The stock of ImmuPharma PLC (LON:IMM) gapped down by GBX 0.106 today and has GBX 37.33 target or 4.00% below today’s GBX 38.89 share price. The 8 months technical chart setup indicates high risk for the GBX 46.32M company. The gap down was reported on Nov, 30 by Barchart.com. If the GBX 37.33 price target is reached, the company will be worth GBX 1.85M less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. The stock decreased 1.54% or GBX 0.61 on November 30, hitting GBX 38.89. About 29,777 shares traded hands. ImmuPharma PLC (LON:IMM) has risen 30.51% since May 3, 2016 and is uptrending. It has outperformed by 25.28% the S&P500.
ImmuPharma PLC (LON:IMM) Ratings Coverage
Out of 2 analysts covering ImmuPharma PLC (LON:IMM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. ImmuPharma PLC has been the topic of 16 analyst reports since September 30, 2015 according to StockzIntelligence Inc. Panmure Gordon maintained the stock with “Buy” rating in Wednesday, September 14 report. The stock of ImmuPharma PLC (LON:IMM) has “Buy” rating given on Tuesday, December 15 by Panmure Gordon. The firm earned “Buy” rating on Tuesday, June 7 by Panmure Gordon. The stock of ImmuPharma PLC (LON:IMM) earned “Buy” rating by Panmure Gordon on Wednesday, September 30. The stock of ImmuPharma PLC (LON:IMM) earned “Buy” rating by Panmure Gordon on Monday, October 24. The company was maintained on Monday, October 24 by Northland Capital. The rating was maintained by Panmure Gordon with “Buy” on Monday, December 7. The stock has “Buy” rating given by Panmure Gordon on Wednesday, November 4. The rating was maintained by Panmure Gordon on Tuesday, June 14 with “Buy”. The rating was maintained by Northland Capital on Monday, June 20 with “Corporate”.
ImmuPharma plc is a drug discovery and development company. The company has a market cap of 46.32 million GBP. The Firm is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. It currently has negative earnings. The Firm has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.